Author Archives: Guest Blogger

Healthcare Nonprofit Bans Genentech Reps

By Randi Hernandez, Pharmaceutical Technology. After a change in distribution strategy at Genentech, Ascension Health has prohibited sales representatives from the drug maker to solicit physicians at Ascension’s 1900 sites of care around the country. The ban is the result of a supply-chain move that routes three infused cancer medications—Avastin (bevacizumab), Rituxan (rituximab), and Herceptin […]
Posted in Guest Blog, healthcare, Sales | Tagged , , | Leave a comment

Five Measures to Cope with the Side Effects of Health Reform

By Sydney Rubin. With more than 8 million Americans now signed up for health insurance through state health exchanges, The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans, many of whom had no health insurance before. People previously rejected by insurers due to pre-existing conditions […]
Posted in Guest Blog, healthcare, Op-Ed, pricing, Regulatory | Tagged , , , | Leave a comment

ePatient Connections: Highlights from This Year’s Summit

This month’s ePatient Connections Summit in Philadelphia, PA, saw biopharmaceutical firms, medical device companies, and patient advocates discuss best practices for engaging patients online and in social media settings. Two main themes arose from the conference: online patient engagement and patient centricity. For the highlights of the event, read Moe Alsumidaie’s Applied Clinical Trials blog […]
Posted in Events | Tagged | Leave a comment

US Company Awarded UK's First "Promising Innovative Medicine" Designation

By Leela Barham. The UK’s Medicines and Healthcare Regulatory Authority (MHRA) has awarded Northwest Biotherapeutics, Inc. (Bethesda, MD) the very first “Promising Innovative Medicine”, or PIM designation, for the company’s DCVax-L product.
Posted in Europe, Global, Guest Blog, Regulatory | Tagged , , , | Leave a comment

UK Postpones Decision on Value-Based Assessment — Again

By Leela Barham. Value-based Pricing (VBP) was first discussed as far back as 2007 by the UK’s consumer authority, the now defunct Office of Fair Trading (OFT).  The general concept of VBP was to set almost provisional prices based on the expected value of new medicines using immature data, with provisions to ‘correct’ the price […]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta